Amgen (FRA:AMG) Total Equity: €7,949 Mil (As of Mar. 2026)


FRA:AMG Amgen Inc FRA:AMG
87 GF Score
Price €313.25
GF Value €305.85
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen Total Equity?

Amgen FRA:AMG -0.24% 87 Total Equity is €7,949 Mil as of Mar. 2026. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €305.85 (Fairly Valued). The stock has 8 warning signs investors should review.

Amgen's total equity for the quarter that ended in Mar. 2026 was €7,949 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Amgen Total Equity Historical Data

* Premium members only.

The historical data trend for Amgen's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Total Equity Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,929.50 3,455.98 5,714.74 5,612.54 7,393.93

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,741.48 6,440.08 8,195.39 7,393.93 7,949.35
FRA:AMG
87GF Score
Amgen Inc FRA:AMG
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Amgen's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=77360.444-69966.512
=7,394

Amgen's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=80015.96-72066.61
=7,949

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €7,949 Mil mean?
Amgen (FRA:AMG) has a Total Equity of €7,949 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Amgen and its competitors.
Is Amgen's Total Equity too high?
Amgen's current Total Equity is €7,949 Mil. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Total Equity compare to GILD and PFE?
Amgen's Total Equity of €7,949 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Amgen and its competitors. Amgen's current Total Equity is €7,949 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €305.85, compared to a current price of €313.25 — trading 2.4% above its estimated fair value. The current Total Equity is €7,949 Mil. Amgen's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Total Equity is €7,949 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €313.25 is trading 2.4% above its estimated GF Value™ of €305.85. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Total Equity: €7,949 Mil
  • GF Value™: €305.85 vs. price of €313.25 (2.4% above fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score

Get the complete analysis for FRA:AMG

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€313.25
Price
€305.85
GF Value